Exact Sciences (EXAS) Competitors $48.49 -0.28 (-0.57%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$49.11 +0.62 (+1.28%) As of 07/25/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, UTHR, NBIX, INCY, EXEL, BMRN, MDGL, HALO, IONS, and RGENShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen United Therapeutics Neurocrine Biosciences Incyte Exelixis BioMarin Pharmaceutical Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Repligen Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends. Does the media refer more to BIIB or EXAS? In the previous week, Biogen had 26 more articles in the media than Exact Sciences. MarketBeat recorded 36 mentions for Biogen and 10 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 1.22 beat Biogen's score of 0.73 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 17 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, BIIB or EXAS? Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Which has better valuation & earnings, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.99$1.63B$10.1312.98Exact Sciences$2.76B3.32-$1.03B-$5.51-8.80 Is BIIB or EXAS more profitable? Biogen has a net margin of 15.07% compared to Exact Sciences' net margin of -36.06%. Biogen's return on equity of 14.03% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.07% 14.03% 8.32% Exact Sciences -36.06%-3.75%-1.68% Do insiders & institutionals have more ownership in BIIB or EXAS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts recommend BIIB or EXAS? Biogen currently has a consensus target price of $186.37, suggesting a potential upside of 41.70%. Exact Sciences has a consensus target price of $70.50, suggesting a potential upside of 45.39%. Given Exact Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95 SummaryExact Sciences beats Biogen on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.20B$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-8.8021.1828.1020.05Price / Sales3.32286.99429.3789.38Price / Cash8.6642.7636.2258.56Price / Book3.748.378.665.87Net Income-$1.03B-$55.19M$3.25B$258.55M7 Day Performance-3.90%5.88%4.22%3.73%1 Month Performance-6.41%17.33%10.51%11.75%1 Year Performance7.04%4.42%34.40%18.03% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.7487 of 5 stars$48.49-0.6%$70.50+45.4%+0.3%$9.20B$2.76B-8.807,000Positive NewsBIIBBiogen4.8103 of 5 stars$122.68-1.8%$186.37+51.9%-42.2%$18.31B$9.82B12.117,605Upcoming EarningsAnalyst RevisionUTHRUnited Therapeutics4.9917 of 5 stars$293.12+0.4%$383.08+30.7%-9.5%$13.22B$2.88B11.701,305Trending NewsUpcoming EarningsInsider TradeAnalyst RevisionNBIXNeurocrine Biosciences4.5095 of 5 stars$131.83-0.1%$163.87+24.3%-9.6%$13.05B$2.36B44.691,800Upcoming EarningsAnalyst ForecastINCYIncyte4.6318 of 5 stars$67.38-0.7%$74.47+10.5%+2.4%$13.04B$4.24B210.572,617Upcoming EarningsInsider TradeEXELExelixis4.7817 of 5 stars$44.26-0.5%$45.28+2.3%+98.6%$12.07B$2.17B20.121,147News CoveragePositive NewsUpcoming EarningsAnalyst ForecastBMRNBioMarin Pharmaceutical4.9857 of 5 stars$56.56-1.3%$93.78+65.8%-31.1%$10.85B$2.85B21.033,040Positive NewsAnalyst ForecastMDGLMadrigal Pharmaceuticals4.2732 of 5 stars$330.94-1.0%$420.63+27.1%+5.3%$7.35B$180.13M-18.3390News CoverageInsider TradeHALOHalozyme Therapeutics4.8531 of 5 stars$55.92-0.9%$62.70+12.1%+4.1%$6.96B$1.08B14.87390Positive NewsIONSIonis Pharmaceuticals4.5355 of 5 stars$41.55-0.5%$57.13+37.5%-18.5%$6.61B$717.25M-13.901,069Upcoming EarningsRGENRepligen4.6454 of 5 stars$114.80-1.2%$170.75+48.7%-8.0%$6.45B$650.43M-255.111,778Upcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
